Souilamas R, Souilamas J, Saueressig M, Pison C, Briot R
Chirurgie thoracique, hôpital européen Georges-Pompidou (HEGP), 20, rue Leblanc, 75015 Paris, France.
Rev Pneumol Clin. 2010 Feb;67(1):50-6. doi: 10.1016/j.pneumo.2010.12.006. Epub 2011 Feb 1.
Lung transplantation has become an established treatment for end-stage pulmonary failure refractory to medical management. However, the scarcity of lung grafts and the growing number of candidates has led to an increase in deaths among patients on waiting lists. Despite improvements in donor management, organ preservation, and the use of marginal and cardiac death donors, only about 20% of candidate lungs are currently being transplanted. A new ex vivo "reconditioning" technique is opening up new perspectives. Indeed, a significant number of rejected lungs can now be retrieved and transplanted with acceptable results. Given the longer storage times provided by this technique, transplantation can be programmed, with better surgical efficiency. A new mobile organ-care machine is currently under evaluation. In near future, a pilot laboratory will be created and dedicated to ex vivo reconditionning of all lung grafts before transplantation and grafts will be sent to lung transplant centers after immunologic cross-matching.
肺移植已成为治疗内科治疗难以奏效的终末期肺衰竭的既定疗法。然而，肺源稀缺以及候选者数量不断增加，导致等待名单上的患者死亡人数上升。尽管在供体管理、器官保存以及边缘供体和心脏死亡供体的使用方面有所改进，但目前仅有约20%的候选肺得到移植。一种新的体外“修复”技术正在开辟新的前景。的确，现在可以获取大量被拒收的肺并进行移植，结果尚可接受。鉴于该技术提供了更长的保存时间，移植可以进行规划，手术效率更高。一种新型移动器官护理机器目前正在评估中。在不久的将来，将创建一个试点实验室，专门用于在移植前对所有肺移植物进行体外修复，并且在免疫交叉配型后将移植物送往肺移植中心。
